Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 11/20 | 0.58 |
| ▸ | PTGS1 | P23219 | 10/20 | 0.58 |
| ▸ | MT-CO2 | P00403 | 3/20 | 0.49 |
| ▸ | CA12 | O43570 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | CA3 | P07451 | 1/20 | 0.49 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.49 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.49 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.49 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.49 |
| ▸ | CA4 | P22748 | 1/20 | 0.49 |
| ▸ | CA6 | P23280 | 1/20 | 0.49 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.49 |
| ▸ | PDE4A | P27815 | 1/20 | 0.49 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.49 |
| ▸ | CA5A | P35218 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4680219 | 0.77 | PTGS2 (0.64) | PTGS2PTGS1MT-CO2CA12CA1 | |
| SCHEMBL2277199 | 0.77 | PTGS2 (1.00) | PTGS2PTGS1MT-CO2CA12CA1 | |
| SCHEMBL5422346 | 0.74 | PTGS2 (0.70) | PTGS2PTGS1MT-CO2CA12CA1 | |
| SCHEMBL5428698 | 0.74 | PTGS2 (0.80) | PTGS2PTGS1MT-CO2CA12CA1 | |
| SCHEMBL14562098 | 0.74 | PTGS2 (0.80) | PTGS2PTGS1MT-CO2CA12CA1 | |
| SCHEMBL18543857 | 0.73 | ALDH1A1 (0.48) | ADORA3L3MBTL1 | |
| SCHEMBL1929139 | 0.73 | L3MBTL1 (0.68) | PTGS2PTGS1MT-CO2CA12CA1 | |
| SCHEMBL3947487 | 0.73 | MAPK14 (0.65) | PTGS2PTGS1MT-CO2CA12CA1 | |
| SCHEMBL4683390 | 0.72 | PTGS2 (0.57) | PTGS2PTGS1MT-CO2CA12CA1 | |
| Sulfamide SCHEMBL4638912 | 0.71 | PTGS2 (0.81) | PTGS2PTGS1MT-CO2CA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1218369-B1 | INHIBITORS OF c-JUN N-TERMINAL KINASES (JNK) AND OTHER PROTEIN KINASES | VERTEX PHARMA (US) | 2008-07-23 | — | — | EP | disclosed |
| US-7169798-B2 | Inhibitors of c-Jun N terminal kinases (JNK) and other protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-01-30 | — | — | US | disclosed |
| US-20050026967-A1 | Inhibitors of c-jun N terminal kinases (JNK) and other protein kinases | GREEN JEREMY (US) | 2005-02-03 | — | — | US | disclosed |
| US-6693108-B2 | PYRIMIDINYL-GUANIDINE DERIVATIVES | VERTEX PHARMACEUTICALS INCORPORATED | 2004-02-17 | — | — | US | disclosed |
| US-20030149051-A1 | Inhibitors of c-Jun N terminal kinases (JNK) and other protein kinases | VERTX PHARMACEUTICALS INCORPORATED | 2003-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030149051-A1 | Inhibitors of c-Jun N terminal kinases (JNK) and other protein kinases | MAPK1, PACSIN2, MAP3K1 | PTGS2 851/4885PTGS1 736/4885MT-CO2 2598/4885 |
| US-20050026967-A1 | Inhibitors of c-jun N terminal kinases (JNK) and other protein kinases | MAP3K2, CSNK1G2, MAP3K5 | PTGS2 461/4885PTGS1 1001/4885MT-CO2 2196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.